| heart failure | versus active treatment No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Nordrehaug, 1992 | hydrochlorothiazide vs benazepril | NYHA functional class improvement 0.06 [0.01; 0.41] | | | | Sievert, 1989 | hydrochlorothiazide+triamterene vs digoxin | | | |
| Trial | Treatments | Patients | Method |
|---|
| Nordrehaug, 1992 | hydrochlorothiazide 50 mg daily (n=29) vs. benazepril 20 mg daily (n=29) | patients with symptomatic (NYHA functional class 2) mild heart failure | double blind Cross over Sample size: 29/29 Primary endpoint: none FU duration: 8 weeks | | Sievert, 1989 | hydrochlorothiazide+triamterene (n=16) vs. digoxin (n=16) | patients in heart failure and sinus rhythm | double blind Cross over Sample size: 16/16 Primary endpoint: haemodynamic response FU duration: 5 weeks |
|
| hypertension | versus placebo or control No demonstrated result for efficacy | 3 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Kuramoto, 1981 | hydrochlorothiazide + triamterene vs placebo | | | cardiovascular death 1.07 [0.23; 5.02] cardiovascular event 0.47 [0.16; 1.43] | | EWPHE, 1985 | hydrochlorothiazide + triamterene vs placebo | cardiovascular death 0.73 [0.55; 0.97] cardiovascular event 0.73 [0.55; 0.97] | | | | EWPHE (subgroup ), 1985 | hydrochlorothiazide vs placebo | | | All cause death 1.17 [0.99; 1.40] coronary death 1.37 [0.56; 3.35] cardiovascular death 1.21 [0.85; 1.73] fatla stroke 1.48 [0.65; 3.38] |
| Trial | Treatments | Patients | Method |
|---|
| Kuramoto, 1981 | hydrochlorothiazide + triamterene (n=44) vs. placebo (n=47) | patients over the age of 60 with sitting diastolic blood pressure on placebo treatment in the range 90-119 mm Hg and a systolic pressure in the range 160-239 mm Hg | double blind Sample size: 44/47 Primary endpoint: FU duration: 4.0y | | EWPHE, 1985 | hydrochlorothiazide + triamterene , hydrochlorothiazide + triamterene (n=416) vs. placebo (n=424)
| patients over the age of 60 with sitting diastolic blood pressure on placebo treatment in the range 90-119 mm Hg and a systolic pressure in the range 160-239 mm Hg
| Double blind Sample size: 416/424 Primary endpoint: FU duration: 4.3 y
| | EWPHE (subgroup ), 1985 | hydrochlorothiazide + triamterene (n=70) vs. placebo (n=85) | patients over the age of 60 | double-blind Sample size: 70/85 Primary endpoint: FU duration: 3·1y |
|
